Abstract
The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself or AS-related diseases. The activation of mTOR signaling contributes to the endothelium dysfunction and the formation of foam cells via enhancing the process from monocyte to macrophage in the initial stage of atherosclerosis. The activation of mTOR signaling not only promotes the formation of the fatty streak (more foam cells), and migration and proliferation of vascular smooth muscle cells in the early lesion of AS, but also facilitates the formation of vulnerable plaque and replication of vascular smooth muscle cells in the late lesion of AS. Moreover, it has been found the role of the upstream and downstream components of mTOR signaling pathway in the formation of AS. Thus, the mTOR inhibitors may be a promising target for the prevention and treatment of AS.
Keywords: Mammalian target of rapamycin, atherosclerosis, mTOR signaling, foam cell, macrophage, vascular smooth muscle cells.
Current Molecular Medicine
Title:Role of Mammalian Target of Rapamycin in Atherosclerosis
Volume: 18 Issue: 4
Author(s): Z. Cai*, Y. He and Y. Chen
Affiliation:
- Department of Neurology, Chongqing General Hospital, University of Chinese Academy of Sciences, 400013, Chongqing,China
Keywords: Mammalian target of rapamycin, atherosclerosis, mTOR signaling, foam cell, macrophage, vascular smooth muscle cells.
Abstract: The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself or AS-related diseases. The activation of mTOR signaling contributes to the endothelium dysfunction and the formation of foam cells via enhancing the process from monocyte to macrophage in the initial stage of atherosclerosis. The activation of mTOR signaling not only promotes the formation of the fatty streak (more foam cells), and migration and proliferation of vascular smooth muscle cells in the early lesion of AS, but also facilitates the formation of vulnerable plaque and replication of vascular smooth muscle cells in the late lesion of AS. Moreover, it has been found the role of the upstream and downstream components of mTOR signaling pathway in the formation of AS. Thus, the mTOR inhibitors may be a promising target for the prevention and treatment of AS.
Export Options
About this article
Cite this article as:
Cai Z. *, He Y. and Chen Y. , Role of Mammalian Target of Rapamycin in Atherosclerosis, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666180926163917
DOI https://dx.doi.org/10.2174/1566524018666180926163917 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rational Discovery of Novel Squalene Synthase Inhibitors through Pharmacophore Modelling
Current Computer-Aided Drug Design Isolated Systolic Hypertension: Epidemiology, Pathogenesis and Treatment
Current Hypertension Reviews A Comprehensive Review on Phytochemistry and Pharmacological Effects of Stinging Nettle (Urtica dioica)
Current Traditional Medicine An Efficient Machine Learning Model for Prediction of Acute Myocardial Infarction
Recent Advances in Computer Science and Communications Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Advanced Echocardiographic Imaging of the Congenitally Malformed Heart
Current Cardiology Reviews Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence
Current Cardiology Reviews Evaluation of Cucurbita Argyrosperma as Anti-Angiogenic Chemopreventive, Anti-Diabetic, Anti-Carcinogenic, and Anti-microbial Therapy
Current Traditional Medicine Seaweed Proteins as a Source of Bioactive Peptides
Current Pharmaceutical Design Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews Biology of Cholesterol Lowering in Atherosclerotic Plaques
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Life and Death Partners in Post-PCI Restenosis: Apoptosis, Autophagy, and The Cross-talk Between Them
Current Drug Targets Resveratrol and Analogues: A Review of Antioxidant Activity and Applications to Human Health
Recent Patents on Food, Nutrition & Agriculture Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia
Current Medicinal Chemistry Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology Apo A-1 Mimetic Peptides as Atheroprotective Agents in Murine Models
Current Drug Targets